SCYNEXIS Inc (SCYX) stock
SCYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3071% below fair value
$2.91−0.30 (-9.35%)
Close on Nov 16, 2026Market cap $28.95MP/E –Yield –
Scynexis EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Scynexis's EPS for the twelve months ending Jun 30, 2026 was -$2.15. For fiscal 2025 it was -$1.36. The highest annual figure on record is $11.12 in fiscal 2023.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.36 | – |
| FY2024 | Dec 31, 2024 | -$3.52 | -131.7% |
| FY2023 | Dec 31, 2023 | $11.12 | – |
| FY2022 | Dec 31, 2022 | -$11.76 | – |
| FY2021 | Dec 31, 2021 | -$10.00 | – |
| FY2016 | Dec 31, 2016 | -$126.40 | – |
| FY2015 | Dec 31, 2015 | -$214.40 | – |
| FY2014 | Dec 31, 2014 | -$215.20 | – |
| FY2013 | Dec 31, 2013 | -$11157.60 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0.63 | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.36 | – |
| Q4 FY2025 | Dec 31, 2025 | $1.94 | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.36 | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.11 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.88 | -1200.0% |
| Q4 FY2024 | Dec 31, 2024 | -$0.73 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.48 | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.40 | -112.2% |
| Q1 FY2024 | Mar 31, 2024 | $0.08 | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.71 | – |
| Q3 FY2023 | Sep 30, 2023 | -$0.32 | – |
| Q2 FY2023 | Jun 30, 2023 | $19.68 | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.68 | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.43 | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.96 | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.48 | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.44 | – |
| Q3 FY2021 | Sep 30, 2021 | -$0.48 | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.76 | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.84 | – |
| Q4 FY2020 | Dec 31, 2020 | -$37.07 | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.24 | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.12 | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.76 | – |
| Q4 FY2019 | Dec 31, 2019 | -$17.53 | -641.0% |
| Q3 FY2019 | Sep 30, 2019 | -$11.60 | -1550.0% |
| Q2 FY2019 | Jun 30, 2019 | -$12.62 | – |
| Q1 FY2019 | Mar 31, 2019 | -$37.16 | – |
| Q4 FY2018 | Dec 31, 2018 | $3.24 | – |
| Q3 FY2018 | Sep 30, 2018 | $0.80 | – |
| Q2 FY2018 | Jun 30, 2018 | -$18.37 | – |
| Q1 FY2018 | Mar 31, 2018 | -$9.60 | – |
| Q4 FY2017 | Dec 31, 2017 | -$21.16 | – |
| Q3 FY2017 | Sep 30, 2017 | -$24.80 | – |
| Q2 FY2017 | Jun 30, 2017 | -$13.01 | – |
| Q1 FY2017 | Mar 31, 2017 | -$20.00 | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.60 | – |
| Q3 FY2016 | Sep 30, 2016 | -$38.40 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?